IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

IDE397 Clinical Phase 1 Interim Plasma Pharmacodynamic Data Robust Plasma SAM Reduction (Targeting >60%) Observed Across All Cohorts Cohort 5 Plasma SAM Reduction Over Cycle 1 Increase in Plasma SAM Inhibition at Higher Exposures 12 IDEAYA Data Plasma SAM (ng/ml) 60 p = 0.049 77% Reduction 0 Pre-tx Post-tx (C2D1) % Plasma SAM inhibition 80 60. 50 40 20 0 0.01x 0.1x 1x 10x 100x IDE397 Plasma Conc 1 1 x-axis concentration scale discloses relative values as indicated C1D1 Pre C1D1 6H C1D15 6H C1D1 Pre: cycle 1 day 1 pre-dose C1D1 6H: cycle 1 day 16hr post dose C1D15 6H: cycle 1 day 15 6hr post dose gsk IDEAVA BIOSCIENCES

View entire presentation